The Unnecessary Uses of Antibiotics During COVID-19 Fulfill Antibiotic Resistance

Authors

Keywords:

Antibiotic, Covid-19, Pandamic, SARS

Abstract

Coronavirus disease-19 (COVID-19) is a critical health challenge in all countries and according to united nation report, one of the most common problems during COVID -19 is the bacterial resistance to antimicrobial drugs that face the health issues which is due to antibiotics misuses during the pandemic disease as a protective to expected secondary bacterial infections after a viral infection. Subsequently COVID-19 early phase courage or enhance this massive antibiotic use in several countries all over the world. The purpose of this review to cover the prevalence and reasons behind these antibiotics misuse and analyze most common antibiotics uses during early-phase COVID-19 pandemic.

References

Yuki K, Fujiogi M and Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol 2020; 215:108427.

Organization WH. Clinical management of COVID-19: interim guidance, 27 May 2020.Organization WH.

Mohammad Zadeh, N. and Sadat Mashinchi Asl, N., 2021. Mechanism and adverse effects of COVID-19 drugs: a basic review. Int J Physiol Pathophysiol Pharmacol, 13(4), pp.102-109.

Sabry NA, Farid SF. et al. Antibiotic dispensing in Egyptian community pharmacies: an observational study. Res Soc Admin Pharm. 2014;10(1):168– 184.

Elmasry AAG, Bakr ASM, Kolkailah DAAA, et al. Pattern of antibiotic abuse– a population-based study in Cairo. 2013;62(1):189-195.

Covid-19 guidelines of the China National Health Commission.

Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community‑acquired pneumonia. An Official Clinical Practice Guide‑ line of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7): e45–67.

International Severe Acute Respiratory and Emerging Infections (ISARIC) Report 27 April 2020. International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC). Available at: https:// emergency medicine cases. com/ (accessed 23rd April 2021).

National Institute for Health and Care Excellence. COVID Rapid Guideline: Antibiotics for Pneumonia in Adults in Hospital. Available online: https://www.nice.org.uk/guidance/ng173 (accessed on 22 October 2020).

Covid N. Rapid guideline: antibiotics for pneumonia in adults in hospital. NICE guideline [NG173]. 2020. Coronavirus Disease 2019 (COVID‑19) Treatment Guidelines. National Institutes of Health, 2020, https://www.covid19treatmentguidelines.nih.gov

Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection, and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Inf 2020;26:1622–1629.

Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York city. N Engl J Med. 2020;382(24):2372–2374.

Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–1629.

LiG, FanY. Corona virus infections and immune responses. Med Virol. 2020;92:424–32.

Elsayed A, Darwish S, Zewail M, Mohammed M, Saeed H and Rabea H. Antibiotic misuse and compliance with infection control measures during COVID‐19 pandemic in community pharmacies in Egypt. International Journal of Clinical Practice. 2021;75(6).

Sabry NA, Farid SF. Antibiotic dispensing in Egyptian community pharmacies: an observational study. Res Soc Admin Pharm. 2014;10(1):168–184.

Elmasry AAG, Bakr ASM, Kolkailah DAAA, et al. Pattern of antibiotic abuse– a population-based study in Cairo. 2013;62(1):189195.

Guaraldi G, Meschiari M, Cozzi-Lepri A. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020;2020: E474–E484. DOI: 10.1016/S2665-9913(20)30173-9.

Langford B, So M, Raybardhan S, Leung V, Soucy J‑P, Westwood D, et al. Antibiotic prescribing in patients with COVID‑19: rapid review and meta‑ analysis. Clin Microbiol Infect. 2021;27:520–31.

Abu‑Rub LI, Abdelrahman HA, Johar ARA, Alhussain HA, Hadi HA, Eltai NO. Antibiotics prescribing in intensive care settings during the covid‑19 era: a systematic review. Antibiotics. 2021;10:1–13.

Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy R, et al. Bacterial infections and patterns of antibiotic use in patients with COVID‑19. J Med Virol. 2021; 93:1489–95.

Langford BJ, So M, Raybardhan S, et al. Bacterial co‑infection and second‑ ary infection in patients with COVID‑19: a living rapid review and meta‑ analysis. Clin Microbiol Infect. 2020. https://doi.org/10.1016/j.cmi.2020.07.

Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. Front Microbiol. 2017;8:1041.

Beović B, Dousak M, Ferreira‑Coimbra J, et al. Antibiotic use in patients with COVID‑19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID‑IRI) survey. J Antimicrob Chemother. 2020. https://doi.org/ 10.1093/jac/dkaa326.

Grigoryan L, Germanos G, Zoorob R, Juneja S, Raphael JL, Paasche-Orlow MK, et al. Use of antibiotics without a prescription in the U.S. population: a scoping review. Ann Intern Med. 2019;171:257–63.

Karampela I, Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COV ID‑19? Arch Med Res. 2020. https://doi.org/10.1016/j.arcmed.2020.06.004.

Ippolito M, Misseri G, Catalisano G, et al. Ventilator-associated pneumonia in patients with COVID-19: a systematic review and meta-analysis. Antibiotics (Basel) 2021;10:545.

Novy E, Scala‑Bertola J, Roger C, et al. Preliminary therapeutic drug monitoring data of β‑lactams in critically ill patients with SARS‑CoV‑2 infection. Anaesth Crit Care Pain Med. 2020;39(3):387–8.

Kanoh S and Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615.

Touret F, Gilles M, Barral K, et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep. 2020;10(1):13093.

Kawamura K, Ichikado K, Takaki M, Eguchi Y, Anan K, Suga M. Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center. Int J Antimicrob Agents. 2018;51(6):918-924.

Pedersen HP, Hildebrandt T, Poulsen A, Uslu B, Knudsen HH, Roed J, et al. Initial experiences from patients with COVID-19 on ventilatory support in Denmark; 2020:4.

Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020. Feb 19;368:m606.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382(18):1708–20.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130(5):2620–9.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.

. Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ. 2020 07;98(7):442-442A.

Norton A. Many COVID-19 patients given useless antibiotics, study finds. Isle of Man, UK: Medical Xpress; Aug 4 2020. Available from: https://medicalxpress.com/news/2020-08-covid- patients-useless-antibiotics.html

World Health Organization.Antimicrobialresistance. https://www.who.int/news-room/factsheets/detail/antimicrobial-resistance.

Huttner BD, Catho G, Pano‑Pardo JR, et al. COVID‑19: don’t neglect antimicrobial stewardship principles. Clin Microbiol Infect.2020;26(7):808–10.

Richter S, Parolin C, Palumbo M, et al. Antiviral properties of quinolone‑ based drugs. Curr Drug Targets Infect Disord. 2004;4(2):111–6.

Suleyman G, Fadel RA, Malette KM, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open. 2020;3(6):e2012270.

Downloads

Published

2022-11-27

How to Cite

Ahmed, A. A. (2022). The Unnecessary Uses of Antibiotics During COVID-19 Fulfill Antibiotic Resistance. Pharmacy and Applied Health Sciences, 1(2), 6–10. Retrieved from https://fccc.knu.edu.iq/index.php/phahs/article/view/13

Issue

Vol. 1 No. 2 (2022): Issue Two

Section

Letter

License

Copyright (c) 2022 Asmaa A. Ahmed, Tariq W. Sadeq

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

All PHAHS Journal articles are published under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0) which allows authors retain copyright and others may not use the material for commercial purposes. A commercial use is one primarily intended for commercial advantage or monetary compensation. If others remix, transform, or build upon the material, they may not distribute the modified material.

Copyright on any research article published by the PHAHS Open Access journal is retained by the author(s). Authors also grant any third party the right to use the article freely as long as its original authors, citation details and publisher are identified.
Use of the article in whole or part in any medium requires attribution suitable in form and content as follows: [Title of Article/Author/Journal Title and Volume/Issue. Copyright (c) [year] [copyright owner as specified in the Journal]. Links to the final article on PHAHS website are encouraged where applicable.
The CC BY-NC-ND 4.0 Creative Commons Attribution License does not affect the moral rights of authors, including without limitation the right not to have their work subjected to derogatory treatment. It also does not affect any other rights held by authors or third parties in the article, including trademark or patent rights, or the rights of privacy and publicity. Use of the article must not assert or imply, whether implicitly or explicitly, any connection with, endorsement or sponsorship of such use by the author, publisher or any other party associated with the article.